Green Cross Health (GXH) H2 2025 earnings summary

Executive summary

• Group revenue reached $523.8m for the year ended 31 March 2025, up 4% year-over-year, driven by acquisitions, strong dispensary performance, and despite inflationary pressures and constrained consumer spending.

• Operating profit increased to $38.7m, reflecting top line growth and operational improvements in both Pharmacy and Medical divisions.

• Net profit after tax attributable to shareholders was $16.0m, with EPS at 11.1 cps.

• Final FY25 dividend of 2.75cps declared, with total dividends for the year at 7.0cps.

• Over $85m invested in technology, site refurbishments, and acquisitions over five years to expand primary care offerings.

Financial highlights

• Pharmacy operating revenue rose 2% to $370.4m, with operating profit up to $21.5m; network expanded to 328 stores.

• Medical operating revenue increased 9% to $153.4m, with operating profit at $19.5m; 416,500 enrolled patients across 65 medical centres.

• Operating cash flow was $52.6m; net cash position of $1.8m as at 31 March 2025.

• Gearing ratio improved to 11.9%; debt/pre-IFRS16 EBITDA at 0.7x; operating profit/interest at 18x.

• Final dividend declared at 2.75 cents per share.

Outlook and guidance

• Focus on expanding clinical services through Care & Advice Health Hubs and advocating for extended pharmacist scope.

• Continued investment in technology, operational efficiency, and team-based care models to address workforce challenges.

• Targeting further store upgrades, expansion of branded health hubs, and beauty offerings.

• Trading performance for the first six months of the new fiscal year expected to be in line with the first half of the reported period.